A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

  • Fedele, Pasquale (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/43880/MonH-2018-153301
NMA SSA Reference Number: SSA/43880/MonH-2018-157644
Monash Health Ref: RES-18-0000-592A
Effective start/end date2/02/191/02/24